Aztherapies.com Website Review

CREATING NOVEL TREATMENTS FOR NEURODEGENERATION AND NEUROINFLAMMATION. Our platform comprises numerous CNS technologies. In addition to our ongoing ALZT-OP1 clinical trial, the Cognite Trial Alzheimer’s disease and other neurodegenerative conditions. We are looking beyond Alzheimer’s disease to conditions such as amyloidosis-related cognitive impairment, st*oke, and Parkinson’s disease. We are also pursuing additional avenues of treatment, such as quality of life with our ALZT-QoL therapy, as well as novel dosing and administration technologies, such as the ALZT-Patch and AZHALER-D Built around technology exclusively licensed from Harvard Medical School and Mas*achusetts General Hospital, our lead product candidate (ALZT-OP1) is a novel combination drug regimen designed to halt Alzheimer’s disease early in its development. ALZT-OP1 takes a two pronged approach to Alzheimer’s disease treatment by both inhibiting neurotoxic amyloid-beta protein aggregation, and by titrating the as*ociated neuroinflammatory response that triggers nerve death and progressive brain damage. We are also pursuing preclinical studies of M1, a reversible acetylcholine esterase inhibitor as a quality of life product candidate, and ALZT-QoL, which will lessen the impact of Alzheimer’s in patients with moderate to severe disease. Additionally, we are developing the AZHALER-D single dose disposable inhalation device, and the ALZT-Patch to facilitate optimal drug dosing and increase patient compliance. Our research is centered around the triggers of Alzheimer’s disease progression, namely the accu*ulation of Amyloid-Beta plaques and concomitant neuroinflammation. Amyloid-Beta accu*ulates into fibrils and plaques in the brain, the oligomeric forms accu*ulating in neuronal synapses causing neurotoxicity and the formation of tau tangles inside of the neurons. This neurotoxicity is exacerbated by a heightened inflammatory response, leading to further damage to the brain.